Dexamethasone Suppression Test Diagnosis
The dexamethasone suppression test (DST) is used to diagnose Cushing's syndrome (endogenous hypercortisolism) by assessing whether cortisol production can be suppressed by exogenous glucocorticoid administration. 1
Primary Diagnostic Purpose
The DST serves as a screening and confirmatory test for Cushing's syndrome, which results from excessive cortisol production either from ACTH-dependent sources (pituitary adenomas causing Cushing's disease, or ectopic ACTH-secreting tumors) or ACTH-independent sources (adrenal tumors). 1
Low-Dose DST (Screening)
The low-dose DST (typically 1 mg overnight) is the primary screening test for suspected Cushing's syndrome, with failure to suppress serum cortisol indicating autonomous cortisol production. 1
The test is particularly useful for shift workers and patients with disrupted circadian rhythms due to uneven sleep schedules, though it may be unreliable in women taking oral estrogen. 1
Measuring dexamethasone levels alongside cortisol the morning after administration improves test interpretability and helps identify false-positive results due to inadequate dexamethasone absorption or compliance. 1, 2
Diagnostic Performance
The low-dose DST demonstrates high sensitivity (100%) for diagnosing Cushing's syndrome when using appropriate cortisol cutoffs, though specificity is more moderate (63-91% depending on the cutoff used). 3
Important caveat: Some patients with confirmed Cushing's disease can suppress cortisol to levels previously thought to exclude the diagnosis—18% suppressed below 5 mcg/dL and 8% below 2 mcg/dL in one series. 4 This means the DST should not be used as the sole criterion to exclude Cushing's syndrome. 4
Optimal cortisol cutoff is 2.1 mcg/dL (sensitivity 92-95%, specificity 93%), with values above this threshold highly suggestive of Cushing's syndrome. 2
Differential Diagnosis Role
Beyond initial screening, the DST also helps differentiate between types of ACTH-dependent Cushing's syndrome:
The low-dose DST can distinguish Cushing's disease from ectopic ACTH syndrome with 82% sensitivity and 79% specificity when evaluating the degree of cortisol suppression at 24 and 48 hours. 5
When combined with CRH stimulation testing (>30% suppression on low-dose DST and/or >20% increase on CRH test), diagnostic accuracy improves dramatically to 97% sensitivity and 94% specificity for differentiating pituitary from ectopic sources. 5
This combined approach eliminates the need for the traditional high-dose DST in most cases, offering equivalent diagnostic information with a safer, more cost-effective protocol. 5
Critical Pitfalls to Avoid
Drug interactions significantly affect DST interpretation: 6
- Phenytoin, phenobarbital, ephedrine, and rifampin enhance dexamethasone metabolism, potentially causing false-negative results. 6
- Indomethacin can cause false-negative results. 6
- Oral estrogen therapy interferes with DST reliability in women. 1
Pseudo-Cushing's states (psychiatric disorders, alcohol use, obesity, PCOS) can produce mildly elevated results on DST, though UFC is typically within 3-fold of normal in these conditions. 1
Inadequate dexamethasone levels account for approximately 6% of non-Cushing's patients with elevated post-DST cortisol, highlighting why reflex dexamethasone measurement should be performed when cortisol fails to suppress. 3
Clinical Algorithm
When Cushing's syndrome is suspected: 1
- Start with low-dose DST (1 mg overnight), measuring both cortisol and dexamethasone levels the following morning
- Cortisol >2.1 mcg/dL suggests Cushing's syndrome; verify adequate dexamethasone level (>4.5 nmol/L) 2, 3
- If positive, measure ACTH to determine ACTH-dependent vs. ACTH-independent disease 1
- For ACTH-dependent cases, combine low-dose DST suppression pattern with CRH stimulation to differentiate Cushing's disease from ectopic ACTH syndrome 5
- Confirm with additional tests (late-night salivary cortisol, 24-hour urinary free cortisol) as no single test is definitive 1